Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

Journal for ImmunoTherapy of Cancer

Volumn 5, Issue 1, 2017, Pages

  Shiuan, Eileen ^a   Beckermann, Kathryn E ^b   Ozgun, Alpaslan ^c   Kelly, Ciara ^d   McKean, Meredith ^e   McQuade, Jennifer ^e   Thompson, Mary Ann ^b   Puzanov, Igor ^h   Greer, John P ^b   Rapisuwon, Suthee ^f   Postow, Michael ^d,g   Davies, Michael A ^e   Eroglu, Zeynep ^c   Johnson, Douglas ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Checkpoint inhibitor; CTLA 4; Immune thrombocytopenic purpura; Melanoma; PD 1; Thrombocytopenia

Indexed keywords

B RAF KINASE; CHECKPOINT KINASE INHIBITOR; IMMUNOGLOBULIN; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; RITUXIMAB; ROMIPLOSTIM; STEROID; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; BONE MARROW BIOPSY; BRAIN HEMORRHAGE; CASE REPORT; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEMALE; GAMMA KNIFE RADIOSURGERY; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; INCIDENCE; MEGAKARYOCYTE; MELANOMA; MIDDLE AGED; MONOTHERAPY; MUCOSAL BLEEDING; PETECHIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CTLA-4 ANTIGEN; FEMALE; HUMANS; IPILIMUMAB; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RITUXIMAB; SKIN NEOPLASMS; THROMBOCYTOPENIA;

EID: 85013287852     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0210-0     Document Type: Article

References (23)

1. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384-91.
2. Wolchok JD. PD-1 blockers. Cell. 2015;162:937.
3. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23-34.
4. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-28.
5. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in advanced Melanoma. N Engl J Med. 2015;372:2521-32.
6. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35.
7. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-13.
8. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-42.
9. Le Roy A, Kempf E, Ackermann F, Routier E, Robert C, Turpin A, Marabelle A, Mateus C, Michot J-M, Lambotte O. Two cases of immune thrombocytopenia associated with pembrolizumab. Eur J Cancer. 2016;54:172-4.
10. Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016;26(2):202-4.
11. Kanameishi S, Otsuka A, Nonomura Y, Fujisawa A, Endo Y, Kabashima K. Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol. 2016;27:546-7.
12. Bagley SJ, Kosteva JA, Evans TL, Langer CJ. Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. Cancer Treat Commun. 2016;6:20-3.
13. Kopecký J, Trojanová P, Kubeček O, Kopecký O. Treatment possibilities of ipilimumab-induced thrombocytopenia-case study and literature review. Jpn J Clin Oncol. 2015;45:381-4.
14. Sajjad MZ, George T, Weber JS, Sokol L. Thrombocytopenia associated with ipilimumab therapy of advanced melanoma at a single institution. ASCO Meet Abstr. 2013;31:9072.
15. Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32:875-87.
16. Song Y, Wang Y-T, Huang X-J, Kong Y. Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia. Ann Hematol. 2016;95:959-65.
17. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;106:2244-51.
18. Aslam R, Hu Y, Gebremeskel S, Segel GB, Speck ER, Guo L, Kim M, Ni H, Freedman J, Semple JW. Thymic retention of CD4 + CD25 + FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood. 2012;120:2127-32.
19. Zhong J, Chen S, Xu L, Lai J, Liao Z, Zhang T, Yu Z, Lu Y, Yang L, Wu X, et al. Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP. Hematology. 2016;21(9):552-57.
20. Birtas Atesoglu E, Tarkun P, Demirsoy ET, Geduk A, Mehtap O, Batman A, Kaya F, Cekmen MB, Gulbas Z, Hacihanefioglu A. Soluble programmed death 1 (PD-1) is decreased in patients with immune thrombocytopenia (ITP): potential involvement of PD-1 pathway in ITP immunopathogenesis. Clin Appl Thromb Hemost. 2016;22:248-51.
21. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-7.
22. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48.
23. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol. 2016;2(10):1346-353.